Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245875 | 0.85 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL6288218 | 0.82 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL3473752 | 0.79 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL6291241 | 0.79 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL7569495 | 0.78 | P2RX7 (0.85) | P2RX7 | |
| SCHEMBL6290778 | 0.77 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL6247207 | 0.77 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL6291252 | 0.76 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL4880401 | 0.76 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL6290777 | 0.75 | P2RX7 (0.72) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927219-B2 | N-alkyl-adamantyl triazinyl benzamide derivatives | PFIZER INC. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030144293-A1 | N-alkyl-adamantyl triazinyl benzamide derivatives | PFIZER INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003042190-A1 | N-ALKYL-ADAMANTYL DERIVATIVES AS P2X7-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-1310493-A1 | N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists | Pfizer Products Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144293-A1 | N-alkyl-adamantyl triazinyl benzamide derivatives | AIFM1, BAD, BID | P2RX7 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.